Pfizer Inc. (NYSE:PFE) Stock Holdings Reduced by Wade G W & Inc.

Wade G W & Inc. lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 12.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,188 shares of the biopharmaceutical company's stock after selling 49,968 shares during the quarter. Wade G W & Inc.'s holdings in Pfizer were worth $10,197,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Briaud Financial Planning Inc purchased a new position in Pfizer in the third quarter valued at about $30,000. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the third quarter worth about $34,000. VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. BMO Capital Markets reaffirmed an "outperform" rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 price objective for the company. Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 2nd. Finally, Argus cut Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $35.86.

Pfizer Price Performance

Shares of PFE stock traded down $0.09 during trading hours on Tuesday, hitting $28.35. The company had a trading volume of 23,511,587 shares, compared to its average volume of 43,130,383. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The firm has a market capitalization of $160.65 billion, a price-to-earnings ratio of -472.92, a PEG ratio of 1.18 and a beta of 0.63. The firm's fifty day moving average is $27.05 and its 200 day moving average is $28.04. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company's revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.23 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.93%. Pfizer's dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.